UnitedHealth Group seen as undervalued with strong long-term growth despite recent price gains and challenges.

UnitedHealth Group remains a strong long-term investment despite recent operational challenges and price increases. Management targets 13–16% bottom-line growth driven by margin recovery, AI investments, and share buybacks. Current valuations suggest significant intrinsic value upside, though short-term gains may be limited due to recent rapid price increases. A potential price correction could offer a better entry point as the company works to restore high growth rates.